IntelGenx Technologies Corp. (IGXT)
- Previous Close
0.1593 - Open
0.1593 - Bid --
- Ask --
- Day's Range
0.1593 - 0.1693 - 52 Week Range
0.1500 - 0.1800 - Volume
37,230 - Avg. Volume
0 - Market Cap (intraday)
29.692M - Beta (5Y Monthly) 2.21
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
www.intelgenx.comRecent News: IGXT
View More
Performance Overview: IGXT
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IGXT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IGXT
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-74.80%
Return on Equity (ttm)
--
Revenue (ttm)
1.05M
Net Income Avi to Common (ttm)
-11.03M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
772k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.98M